

Index

Note: When they fall on a page not covered by the text reference, figures are indicated by ‘f’, and tables by ‘t’.

- acute infection, in immunocompetent patients
 - asymptomatic illness 128–30
 - cardiac involvement 140–1
 - central nervous system involvement 138–40
 - factors influencing 125–8
 - general symptoms 130, 131f
 - haemopoietic system involvement 137
 - hepatitis 134–5
 - links with other illnesses 142–3
 - lymphadenopathy 132–4
 - myositis 141
 - progression of infection 131, 132f
 - respiratory system involvement 136
 - reticulo-endothelial system 131, 132f
 - skin lesions 142
 - splenomegaly 135–6
- age distribution of infection 80–1
- AIDS patients *see* HIV-infected patients
- antigens of *T. gondii* 15–17
- Apicomplexa, phylogenetic analysis 1, 2f
- arprinocid 330–1
- artemisinin (qinghaosu) 330
- asexual cycle, in definitive host 4
- asymptomatic infection, in immunocompetent patients 128–30
- atovaquone 327–8
- azalides 325–6
- azithromycin 325–6
- biochemistry of *T. gondii* 17
- bone marrow transplants, transplant-acquired infection 183–4
- bradyzoites
 - culture 25–6
 - and lifecycle of *T. gondii* 1–5, 6f
 - morphology 9–12
- brain infection *see* encephalitis
- cancer, and *T. gondii* infection 184–5
 - treatment protocols 382
- cardiac disease
 - in HIV-infected patients 153
 - in immunocompetent patients 140–1
 - case definitions *see* classification
- cats, as definitive host
 - and disease prevention strategies 103–5
 - and lifecycle of *T. gondii* 1–4
 - transmission of infection by oocysts 74–6
 - vaccination 366–7
 - epidemiology 363
- cattle, infection, clinical pathology 92
- central nervous system infection *see* encephalitis
- chemotherapy
 - arprinocid 330–1
 - artemisinin (qinghaosu) 330
 - atovaquone 327–8
 - azalides 325–6
 - clindamycin 327
 - clinical scope 320–2
 - congenital infection 269–74, 345–8, treatment protocol 381
 - dapsone 328–9
 - 5-fluorouracil 331
 - foetal infection 206–9, 343–5, 385f, treatment protocol 380–1
 - HIV-infected patients 157–64, 332–7
 - maintenance therapy 339–40
 - prophylactic treatment 340–3
 - side-effects 337–8
 - treatment protocols 382–4
 - and immune response 319–20
 - immunocompetent patients 332, treatment protocols 379
 - immunomodulators 331–2
 - immunosuppressed patients 186–7, 343
- infants *see* neonates
- ketolide antibiotics 330
- macrolides 325–7
- malignancies 186–7, treatment protocol 382
- maternal infection 343–5
- neonates 269–72, 345–8, treatment protocol 381
- ocular infection 286–9, 348–9
- pentamidine 330
- piritrexim 330
- poloxamers 331
- pyrimethamine 322–4
- rifabutin 330
- sulphonamides 323–5

392 Index

- chemotherapy (*cont.*)
 - tetracyclines 329
 - transplants 186–7, treatment protocol 381–2
 - treatment protocols 377–84
 - trimethoprim–sulphamethoxazole 324–5
 - trimetrexate 328
 - trovafloxacin 329
 - chronic active infection
 - in immunocompetent patients 128–30
 - laboratory diagnosis 302–3
 - treatment protocols 379
 - chronic fatigue syndrome, association with toxoplasmosis 139–40
 - clarithromycin 325–6
 - classification, infection categories and case definitions 387–90
 - clindamycin 327
 - congenital infection
 - birth prevalence 215–17
 - chemotherapy 269–74, 345–8
 - classification 388
 - clinical features 198–201, 255–9
 - clinical syndromes 259–63
 - diagnosis 263–4
 - epidemiology 254
 - foetal pathology 264–5
 - history 254
 - immunology 47–8
 - incidence 197–8, 199t
 - laboratory diagnosis 202–5, 311–13, 314t
 - management 206–9, 385
 - pathogenesis 266–9
 - prognosis 265–6
 - screening for *see* prenatal screening, and newborn screening
 - and symptom risk 230–1
 - treatment protocols 381
 - connective tissue disease, and *T. gondii* infection 186
 - corticosteroid treatment, and *T. gondii* infection 185–6
 - culture of *T. gondii* 24–6, 27f, 28f
 - laboratory diagnosis of infection 299t
 - cystozoites *see* bradyzoites
 - dapsone 328–9
 - definitive feline host *see* cats, as definitive host
 - diagnosis of infection *see* laboratory diagnosis of infection
 - disease prevention
 - health education 107–8, 231
 - and host infection 103–5
 - hygiene measures 104t, 105, 386
 - occupational measures 107
 - and raw/lightly cooked meat 104t, 105–7
 - domestic cats *see* cats, as definitive host
 - dye test *see* Sabin–Feldman test
 - encephalitis
 - chemotherapy 157–64
 - maintenance therapy 339–40
 - prophylactic treatment 340–3
 - side-effects 337–8
 - treatment protocols 332–7, 382–4
 - diagnosis 154–7
 - epidemiology 147–9
 - in immunocompetent patients 138–9
 - immunology 49–51
 - prevention 164–5
 - prophylactic treatment 163–4
- entero-epithelial stages (types)
lifecycle 2–4
morphology 12–14
- enzyme immunoassay (EIA) 298–300
- epidemiology of infection
HIV-infected patients 147–9
incidence 65–8
 - time trends 68–74
ocular infection 278–80
prevalence 58–65
transmission of infection
 - disease prevention strategies 103–8
 - nonoral acquisition 100–3
 - oocyst ingestion 74–91
 - tachyzoite ingestion 99–100
 - tissue cyst ingestion 91–9
- ethnic distribution of infection, and ingestion of oocysts 83–4
- evolution of *T. gondii*, and vaccine design 360
- extra-intestinal cycle, in definitive host 4
- Felidae, as definitive host *see* cats, as definitive host
- 5-fluorouracil 331
- focal retinochoroiditis *see* ocular infection
- foetal infection
 - classification 387–8
 - clinical features 198–201
 - incidence 197–8, 199t
 - laboratory diagnosis 202–5, 310t, 311–12, 314t
 - management 206–9, 385
 - pathology 264–5
- folic acid antagonists 322–5
- genome of *T. gondii* 14–15
- geographical distribution of infection, and ingestion of oocysts 59–63t, 77–80
- goats, infection, clinical pathology 92
- haemopoietic system, infection with *T. gondii* 137
- health education
 - and disease prevention 107–8
 - and prenatal screening 231
- heart, infection
 - in HIV-infected patients 153
 - in immunocompetent patients 140–1
- heart transplants, transplant-acquired infection 180–2
- hepatitis 134–5
- histopathology, laboratory diagnosis of infection 149–53, 264–5, 299t, 302
- historical perspective xiii–xiv, 1
- HIV-infected patients, *T. gondii* infection

393 Index

- chemotherapy 157–64
 - maintenance therapy 339–40
 - prophylactic treatment 340–3
 - side-effects 337–8
 - treatment protocols 332–7, 382–4
- diagnosis 154–7
 - laboratory tests 307–8, 309t
- epidemiology 147–9
- immunology 48–9
- pathology and clinical features 149–53
- prevention 164–5
- vaccination 363
 - see also* immunosuppressed patients
- host–parasite relationship
- host cell invasion 18
- host pathogenicity 18–21, 22f
- hosts, for *T. gondii* *see* cats, as definitive host;
intermediate host
- humoral immune response 47
- hygiene measures, for disease prevention 104t,
105, 386
- IgG avidity assay 299t, 300
- immunisation *see* vaccines
- immunocompetent patients, *T. gondii* infection
 - asymptomatic illness 128–30
 - cardiac involvement 140–1
 - central nervous system involvement 138–40
 - chronic active infection 140, 302
 - factors influencing 125–8
 - general symptoms 130, 131f
 - haemopoietic system involvement 137
 - hepatitis 134–5
 - laboratory diagnosis 302–4, 305t
 - links with other illnesses 142–3
 - lymphadenopathy 132–4
 - myositis 141
 - progression of infection 131, 132f
 - respiratory system involvement 136
 - reticulo-endothelial system 131, 132f
 - skin lesions 142
 - splenomegaly 135–6
 - treatment protocols 332
 - acute infection 379
 - chronic active infection 379
- immunodeficient patients *see* HIV-infected
patients
- immunology of infection
 - congenital infection in immunocompromised
patients 47–8
 - encephalitis 49–51
 - immunodeficient patients 48–9
 - natural resistance to infection 24
 - pathogenesis 43–4
 - protective immunity
 - humoral immune response 47
 - interferon- γ 46–7
 - T-cell response 44–6
 - time course of immune response 297
 - and vaccine design 360–1
- immunomodulators 331–2
- immunosorbent agglutination assay (ISAGA)
299t, 300
- immunosuppressed patients, *T. gondii* infection
178–9
 - and anticancer chemotherapy 186
 - chemotherapy 186–7, 343
 - and connective tissue disease 186
 - and corticosteroid use 185–6
 - diagnosis 187–9
 - laboratory tests 304, 306, 309t
 - immunology 48–9
 - and malignancy 184–5
 - transplant patients 179–84
 - see also* HIV-infected patients
- incidence
 - of *T. gondii* infection 65–8
 - time trends 68–74
- interferon- γ , and protective immunity 46–7
- intermediate host
 - and disease prevention strategies 103–5
 - and lifecycle of *T. gondii* 3f, 4–5
 - vaccination 365–6
 - epidemiology 363
- intestinal epithelium, and lifecycle of *T. gondii*
1–5, 6f
- ketolide antibiotics 330
- kidney transplants, transplant-acquired infection
182
- laboratory diagnosis of infection 296–7
 - assays 298–302
 - chronic active infection 302–3, 305t
 - foetal infection 202–5, 310f, 311–12, 314t
 - HIV-infected patients 307–8, 309t, 314
 - immunocompetent patients 302–4, 305t
 - immunosuppressed patients 304, 306, 309t
 - maternal infection 194–6, 308, 310–11, 314, 314t
 - neonatal infection 247–9, 250t, 312–13, 314t
 - ocular infection 286, 303, 305t
 - preconception screening 303–4, 305t
 - statistical characteristics 314–16
 - transplant patients 306–7, 309t
- latent infection, in immunocompetent patients
128–30
- ‘latent’ stage of *T. gondii* 43–4
- lifecycle of *T. gondii* 1–5, 6f
- liver
 - infection 134–5
 - transplant-acquired infection 183
- livestock
 - transmission of infection via tissue cysts 91–3
 - vaccination 363
- lung transplants, transplant-acquired infection
180, 182
- lymphadenopathy 132–4
- macrogametes, morphology 12, 13–14
- macrolides 325–7
- malignancy, and *T. gondii* infection 184–5
 - treatment protocols 382

394 Index

- maternal infection
 - chemotherapy 343–5
 - treatment protocols 380–1
- classification 387
- clinical features 194
- incidence 193–4
- infection before pregnancy 196–7
- laboratory diagnosis 194–6, 308, 310–11, 314
- management 206–9, 385
- meat
 - contamination with tissue cysts 93–9
 - cooking, and prevention of infection 105–7
- microgametes, morphology 12, 14
- microscopy, laboratory diagnosis of infection 149–53, 264–5, 299t, 302
- morphology
 - bradyzoites 9–12
 - entero–epithelial stages (types) 12–14
 - macrogametes 12, 13–14
 - microgametes 12, 14
 - oocysts 12, 14
 - sporocysts 14
 - sporozoites 12, 14
 - tachyzoites 5–9
 - tissue cysts 9–12
- muscle, infection 141
- myalgic encephalomyelitis, association with toxoplasmosis 139–40
- myocarditis, in HIV-infected patients 153
- natural resistance to *T. gondii* 24
- neonatal infection, laboratory diagnosis 312–13, 314t
- newborn screening
 - approaches to 241
 - appropriateness of 242
 - biological considerations 245–6
 - clinical impact 251
 - economic considerations 247
 - feasibility 244
 - follow-up 250–1
 - and incidence of infection 242
 - methodology 247–51
 - pathology and clinical features 149–53
 - sensitivity 243–4
 - sociological considerations 246–7
 - and treatment availability 244–5
- nonoral transmission 100–3
- occupational risk of infection 100–3, 107
- ocular infection
 - chemotherapy 286–9, 348–9
 - treatment protocols 380
 - clinical features 284–5
 - diagnosis 285–6
 - differential diagnosis 285
 - epidemiology 278–80
 - histopathology 283–4
 - history 277–8
 - in HIV-infected patients 152–3
 - laboratory diagnosis 303, 305t
 - in neonates and infants 255–6
 - pathogenesis 280–3
- oocysts
 - cultivation 26, 27f, 28f
 - morphology 12, 14
 - transmission of infection
 - antibody prevalence risk factor studies 85–7
 - epidemiological studies 77–85
 - lifecycle evidence 74–6
 - recent infection studies 87–91
- oral transmission *see* transmission of infection
- parasitaemia 137
- pathogenicity of host 18–21, 22f
 - and natural resistance 24
- pentamidine 330
- pigs, infection, clinical pathology 92
- piritrexim 330
- poloxamers 331
- polymerase chain reaction (PCR) technique 299t, 300–1
- post-viral fatigue syndrome, association with toxoplasmosis 139–40
- preconception infection 196–7
 - laboratory screening tests 303–4, 305t
- prenatal infection *see* maternal infection
- prenatal screening
 - adverse effects 232–4
 - benefits 221
 - controversies 214–15
 - foetal infection 228–9
 - health education 231
 - informed decision-making 235–6
 - legal considerations 234–5
 - and prevalence of infection 215–17
 - serological tests 222–4, 225t, 226t, 314–16
 - and symptom risk 217–21, 230–1
 - termination of pregnancy 229
 - and treatment 226–7, 228–9, 229–30
- prevalence, of *T. gondii* infection
 - humans 58–65
 - meat animals 93–5
 - retail meat 93–5
- prophylactic treatment
 - in HIV-infected patients 163–4, 340–3, 383–4
 - in immunosuppressed patients 186–7, 382
- pulmonary toxoplasmosis 136
 - in HIV-infected patients 151–2
- pyrimethamine 322–4
- qinghaosu (artemisinin) 330
- resistance to infection 24
- respiratory system, infection 136
 - in HIV-infected patients 151–2
- reticulo-endothelial system, infection 131, 132f
- retinchoroiditis *see* ocular infection
- rifabutin 330
- roxithromycin 325–7
- Royal Free disease, association with toxoplasmosis 139–40

395 Index

- Sabin–Feldman Dye test 298, 299t
 - seasonal distribution of infection 83
 - seroprevalence of *T. gondii* 58–65
 - sex distribution of infection 81–3
 - sheep, infection, clinical pathology 92
 - skin, infection 142
 - socioeconomic distribution of infection 85
 - spiramycin 325
 - spleen, infection 135–6
 - sporocysts, morphology 12, 14
 - sporozoites
 - and lifecycle of *T. gondii* 1–5
 - morphology 12, 14
 - sporulation 14
 - strain differences of *T. gondii* 21–2
 - sulphamethoxazole 324–5
 - sulphonamides 323–5
 - symptomatic infection, in immunocompetent patients *see* acute infection, in immunocompetent patients
 - systemic lupus erythematosus (SLE), and *T. gondii* infection 186
 - T-cell response, and protective immunity 44–6
 - tachyzoites
 - culture 24–6
 - and lifecycle of *T. gondii* 1–5, 6f
 - morphology 5–9
 - transmission of infection 99–100
 - taxonomy 1, 2f
 - temperature-sensitive *T. gondii* strains, and vaccines 361–2, 365–6, 367–8
 - tetracyclines 329
 - tissue cysts
 - culture 25–6
 - formation and rupture 12
 - morphology 9–12
 - transmission of infection
 - antibody prevalence risk factor studies 97
 - epidemiological studies 95–7
 - lifecycle evidence 91–3
 - meat animal surveys 93–5
 - recent infection studies 98–9
 - transmission of infection
 - disease prevention strategies 103–8, 386
 - nonoral acquisition 100–3
 - oocyst ingestion
 - antibody prevalence risk factor studies 85–7
 - epidemiological studies 77–85
 - lifecycle evidence 74–6
 - recent infection studies 87–91
 - routes of transmission 74, 75t
 - tachyzoite ingestion 99–100
 - tissue cyst ingestion
 - antibody prevalence risk factor studies 97
 - epidemiological studies 95–7
 - lifecycle evidence 91–3
 - meat animal surveys 93–5
 - recent infection studies 98–9
 - transplant-acquired infection 179–80
 - bone marrow transplants 183–4
 - chemotherapy 343
 - treatment protocols 381–2
 - heart/lung transplants 180–2
 - kidney transplants 182
 - laboratory diagnosis 306–7, 309t
 - liver transplants 183
- treatment protocols 379–85
 - trimethoprim 324–5
 - trimetrexate 328
 - trophozoites *see* tachyzoites
 - trovaflaxacin 329
 - twins, infection in, clinical patterns 259, 260f
 - vaccines
 - design of 360–2
 - efficacy 371–2
 - epidemiology 362–3
 - experimental models 364–5
 - killed vaccines 367–9
 - live vaccines
 - for definitive feline host 366–7
 - for intermediate hosts 365–6
 - recombinant/subunit vaccines 369–70
 - virulence to *T. gondii* 23–4
 - wild animals, infection, clinical pathology 93